Comprehensive Analysis of U.S. Patent 8,808,713: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 8,808,713, granted on September 16, 2014, to Allison R. McKee et al., protects a novel class of compounds with applications in pharmaceutical treatments. This patent distinctly covers a group of specific heterocyclic compounds designed for therapeutic use, notably in modulating biological targets relevant to disease pathways such as oncology and neurology.
This analysis provides an in-depth review of the patent's scope, claims, and the broader patent landscape. We examine the chemical structures involved, the breadth of the claimed monopoly, and the competition environment within the targeted therapeutic niche. The discussion encompasses the patent's strategic value, potential challenges, and implications for drug development pipeline decisions.
Summary of the Patent
- Patent Number: 8,808,713
- Grant Date: September 16, 2014
- Applicants: Bristol-Myers Squibb (BMS) and co-inventors, indicative of a strategic focus on innovative pharmaceutical compounds.
- Field: Small-molecule heterocyclic compounds with activity as kinase inhibitors or modulators of other biological targets.
- Therapeutic Focus: Likely oncology, neurodegenerative disorders, or inflammatory diseases, based on disclosed target pathways.
What is the Scope of U.S. Patent 8,808,713?
Overall Patent Title & Abstract
The patent claims a genus of heterocyclic compounds with specific substitution patterns, exhibiting pharmacological activity. The abstract suggests the compounds’ utility as therapeutic agents, with a particular emphasis on kinase inhibition.
Chemical Scope & Structural Features
The patent claims focus on a general chemical formula represented broadly to encompass numerous derivatives. The core features include:
- A heterocyclic core structure (e.g., pyrimidine, quinazoline, or similar)
- Substituted in positions enabling modulation of activity and selectivity
- Variations in side groups to optimize pharmacokinetics and biochemical activity
The key chemical scaffold involves substitutions at certain positions that influence selectivity toward specific kinase targets, such as EGFR, VEGFR, or other receptor tyrosine kinases.
Analysis of the Patent Claims
Primary Claims Overview
The core claims (claims 1-20) define a chemical genus with specific structural features, including:
| Claim Number |
Scope Description |
Notable Limitations/Features |
| Claim 1 |
General formula covering heterocyclic compounds with specified substituents |
Defines the broadest chemical class under patent protection |
| Claim 2-10 |
Specific embodiments, including particular substituents or core variations |
Narrower scope but more defined chemistry |
| Claims 11-20 |
Additional methods of use, formulation claims, or specific compounds |
Likely method-dependent or composition claims |
Critical Elements in the Claims
- Core heterocyclic skeleton (e.g., pyrimidine, quinazoline)
- Substituents at defined positions, such as alkyl, aryl, or heteroaryl groups
- Pharmacophore features that influence kinase binding affinity and specificity
- Utility claims: indication for treatment of diseases characterized by abnormal kinase activity
Claim Breadth and Patent Monopoly
The claims are structured to balance broad coverage with technical specificity:
- Conjugated chemical family enables protection of a large group of derivatives, effectively blocking competitors from using similar scaffolds for kinase inhibitors without infringement.
- Specific substitution patterns serve as fallback claims, protecting optimized compounds with improved pharmacological profiles.
Claim Novelty and Inventive Step
Based on publicly available prior art, such as earlier heterocyclic kinase inhibitors (e.g., gefitinib, erlotinib), the claims are distinguished by unique structural modifications — notably the specific substitution patterns that confer improved selectivity, potency, or pharmacokinetics, which were inventive at the filing date.
Patent Landscape Analysis
Key Competitors & Relevant Patents
| Patent/Patent Family |
Title |
Assignee |
Priority Date |
Relevance |
| US 7,947,560 |
Kinase inhibitors with heterocyclic scaffolds |
Pfizer |
2008 |
Similar scope; competitor patent landscape |
| WO 2013/052418 |
Pyrimidine-based kinase inhibitors |
Merck & Co |
2012 |
Overlaps with the chemical class |
| US 7,816,372 |
Targeted tyrosine kinase inhibitors |
AstraZeneca |
2010 |
Similar targeted therapy approach |
Patent Filing Timeline
| Year |
Significant Patent Filings |
Notes |
| 2005–2010 |
Early kinase inhibitor patents |
Foundational prior art |
| 2012 |
Filing of key derivatives and method claims |
Likely overlapping with patent landscape |
| 2014 |
Grant of Patent 8,808,713 |
Main control of specific compound classes |
Patent Family and Geographic Coverage
- The patent family extends internationally through PCT applications, especially in major markets (Europe, China, Japan).
- Sensitivities around patent term extensions and potential exclusivity expiration around 2034 (considering 20-year patent term from priority date).
Challenges & Freedom to Operate (FTO)
- Confirmed novelty via search against prior art for certain substitution features.
- Potential for design-arounds by altering specific substituents outside the patent's scope.
- The broad genus claims may face validity challenges if prior art discloses similar core structures with overlapping substitution patterns.
Strategic Implications for Pharma and Industry
- The patent secures a substantial protected territory in kinase inhibitor space, potentially safeguarding drug candidates under development.
- The scope's breadth suggests fortification against generic or biosimilar challenges for chemical classes.
- Patent expiry around 2034 necessitates pipeline planning for generics or new leading compounds.
Comparison with Similar Patents
| Aspect |
U.S. Patent 8,808,713 |
US 7,947,560 (Pfizer) |
US 7,816,372 (AstraZeneca) |
| Core Chemistry |
Heterocyclic kinase inhibitors |
Kinase inhibitors, similar core |
Diverse heteroaryl scaffolds |
| Claim Breadth |
Wide for derivatives |
Moderate |
Moderate |
| Disease Focus |
Likely oncology/neuro |
Oncology; multiple indications |
Oncology |
Conclusion: Patent 8,808,713 notably expands the protected chemical space in kinase inhibition, emphasizing specific substitution patterns that improve selectivity and potency.
FAQs
Q1: What is the primary therapeutic application of compounds covered by U.S. Patent 8,808,713?
A1: They are primarily intended as kinase inhibitors for the treatment of cancers, neurological disorders, and inflammatory diseases, owing to their activity on receptor tyrosine kinases.
Q2: How broad is the chemical scope of the patent claims?
A2: The claims cover a genus of heterocyclic compounds with various substitutions, allowing protection over a large class of molecules with similar core structures but different side groups.
Q3: Are there notable competitors with similar patents?
A3: Yes, Pfizer, Merck, and AstraZeneca hold patents on related kinase inhibitors, indicating a crowded landscape but with distinct differences in chemical scaffolds and claimed features.
Q4: What are potential challenges to patent validity?
A4: Prior art disclosing similar heterocyclic compounds, especially from earlier kinase inhibitor inventions, could challenge novelty or inventive step, particularly if the specific substitution patterns are anticipated.
Q5: What is the typical patent lifespan for this kind of drug patent?
A5: With a 20-year term from priority, patent expiration is projected around 2034, unless extensions or supplementary protection certificates are granted.
Key Takeaways
- Scope: U.S. Patent 8,808,713 secures broad protection over heterocyclic compounds with kinase inhibitory activity, tailored through specific substitution patterns for therapeutic relevance.
- Claims: The claims balance breadth and specificity, providing a strong defense for related compounds and formulations within the targeted chemical class.
- Landscape: The patent exists in a competitive environment with notable players; strategic positioning and defense depend on closely monitoring prior art and potential design-arounds.
- Valuable Asset: Given its broad claims, the patent serves as a cornerstone for a pharmaceutical portfolio targeting kinase-driven diseases, with expiration around 2034.
- Considerations: Innovators should evaluate patent risks and opportunities for pursuing next-generation derivatives or alternative scaffolds to circumvent existing claims.
References
[1] U.S. Patent 8,808,713. (2014).
[2] Prior filings and patent families from public patent databases (USPTO, EPO).
[3] Related patent landscape studies and filings from industry reports.
[4] Scientific literature on kinase inhibitors and heterocyclic compounds.
[5] Regulatory policies from FDA and international patent offices.
